Table 5. Efficacy of EGFR-TKIs therapy in stage IV NSCLC patients with various demographic and clinical features.

Characteristics		No. of cases	ORR (%)	P	DCR (%)	P
Overall		94	74.5	-	97.9	-
Gender	Male	49	77.4	0.875	100	0.884
	Female	45	77.8		95.6
Age (years)	≤ 60	58	81	0.513	98.3	1
	> 60	36	63.9		97.2
Smoking status	No	73	78.1	0.697	97.3	1
	Yes	21	61.9		100
Pathologic type	Adenocarcinoma	86	76.7	0.559	97.7	1
	Non-adenocarcinoma	8	50		100
Brain metastasis	Yes	33	75.8	1	97	1
	No	61	73.8		98.4
Timing of targeted therapy	First line	28	85.7	0.612	100	1
	Second or higher line	66	69.7		96.7
ECOG score	0–1	54	94.4	0.049	100	0.883
	≥ 2	40	47.5		95
Type of EGFR mutation (64 cases)	19del	37	70.2	1	97.3	1
	21L858R	27	66.7		96.3

ORR, objective response rate; DCR, disease control rate.